C12Y 304/21007
Plasmin , i.e. fibrinolysin
Official title: Plasmin (3.4.21.7), i.e. fibrinolysin
C12Y304/21007 (Plasmin , i.e. fibrinolysin) appears on 211 US grants and 264 published applications in this corpus.
Search patents in C12Y- Granted patents
- 211
- Published applications
- 264
- Assignees
- 107
- Inventors
- 414
- Latest grant
- 17 Mar 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 2 | 0 |
| 1977 | 0 | 0 |
| 1978 | 1 | 0 |
| 1979 | 0 | 0 |
| 1980 | 0 | 0 |
| 1981 | 3 | 0 |
| 1982 | 3 | 0 |
| 1983 | 0 | 0 |
| 1984 | 3 | 0 |
| 1985 | 0 | 0 |
| 1986 | 1 | 0 |
| 1987 | 0 | 0 |
| 1988 | 2 | 0 |
| 1989 | 1 | 0 |
| 1990 | 1 | 0 |
| 1991 | 1 | 0 |
| 1992 | 2 | 0 |
| 1993 | 2 | 0 |
| 1994 | 4 | 0 |
| 1995 | 4 | 0 |
| 1996 | 3 | 0 |
| 1997 | 4 | 0 |
| 1998 | 11 | 0 |
| 1999 | 8 | 0 |
| 2000 | 4 | 0 |
| 2001 | 7 | 3 |
| 2002 | 6 | 10 |
| 2003 | 4 | 11 |
| 2004 | 3 | 17 |
| 2005 | 4 | 5 |
| 2006 | 2 | 2 |
| 2007 | 1 | 5 |
| 2008 | 5 | 4 |
| 2009 | 6 | 7 |
| 2010 | 3 | 9 |
| 2011 | 5 | 8 |
| 2012 | 9 | 13 |
| 2013 | 7 | 12 |
| 2014 | 5 | 36 |
| 2015 | 13 | 6 |
| 2016 | 8 | 7 |
| 2017 | 7 | 11 |
| 2018 | 7 | 9 |
| 2019 | 7 | 26 |
| 2020 | 7 | 9 |
| 2021 | 8 | 9 |
| 2022 | 8 | 5 |
| 2023 | 10 | 19 |
| 2024 | 2 | 10 |
| 2025 | 6 | 3 |
| 2026 | 1 | 8 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Method and drug for treating spinal muscular atrophy17 Mar 2026US 12,576,139 B2Talengen International Limited
- Plasminogen for use in treating and preventing lung dysfunction16 Dec 2025US 12,497,607 B2Previpharma Consulting GmbH
- Compositions and methods for inhibiting LPA expression7 Oct 2025US 12,435,336 B2Dicerna Pharmaceuticals, Inc.
- Magnetic particle control and visualization29 Jul 2025US 12,370,259 B2Pulse Therapeutics, Inc.
- Methods and materials for using fibrin supports for retinal pigment epithelium transplantation20 May 2025US 12,303,617 B2Mayo Foundation for Medical Education and Research
- Plasmin-induced internal limiting membrane digestion facilitates donor retinal ganglion cell transplantation8 Oct 2026US 2026/0306549 A1University of Pittsburgh—Of the Commonwealth System of Higher Education
- Oligonucleotide fragments and methods of making rnai agents using the same6 Aug 2026US 2026/0226459 A1Eli Lilly and Company
- Freeze-dried plasma (fdp) for well-balanced coagulation and fibrinolysis, method of preparation and use thereof9 Jul 2026US 2026/0191903 A1Army Medical University, People's Liberation Army, Prc
- In vivo production of proteins25 Jun 2026US 2026/0174909 A1ModernaTX, Inc.
- Method for promoting pathological tdp-43 protein degradation, and drug18 Jun 2026US 2026/0166131 A1Talengen International Limited
Most cited
By later US patents
- Modified polynucleotides for the production of biologics and proteins associated with human disease196US 8,999,380 B2Moderna Therapeutics, Inc. · 2015
- Modified polynucleotides for treating protein deficiency194US 9,061,059 B2Moderna Therapeutics, Inc. · 2015
- Blood coagulation factors and process for their manufacture135US 4,297,344 ABehringwerke Aktiengesellschaft · 1981
- Modified polynucleotides encoding copper metabolism (MURR1) domain containing 1124US 9,095,552 B2Moderna Therapeutics, Inc. · 2015
- Modified polynucleotides encoding citeD4124US 9,114,113 B2Moderna Therapeutics, Inc. · 2015